Sanara MedTech revenue up 42% to $65M in FY2023; net loss narrows to $4.4M

Sanara MedTech Inc.

FY2023 net revenue of $65.0M, up 42% from $45.8M in FY2022.
Q4 2023 record sales of $17.7M; net loss of $0.3M vs $4.2M loss in Q4 2022.
FY2023 net loss of $4.4M, improved from $8.1M loss in FY2022.
Adjusted EBITDA negative $0.3M for FY2023 vs negative $7.5M in prior year; Q4 breakeven.
Launched ALLOCYTE Plus and BIASURGE; signed exclusive license with Tufts University for peptide tech.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Sanara MedTech Inc. reported the quarter and year ended December 31, 2023 results: revenue $17.7 million, net income net loss of $0.3 million.

Period: the quarter and year ended December 31, 2023
Revenue: $17.7 million
Net income: net loss of $0.3 million
Result: reported results

Exact text from the filing

outcomes and reduce costs throughout the U.S.” Strategic and Operational Highlights in the Fourth Quarter 2023 ● In the fourth quarter 2023, the Company generated a record $17.7 million in sales, representing a ninth record revenue quarter for the Company. ● For the three months ended December 31, 2023, the Company had a net loss of $0.3 million, compared to

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Sanara MedTech Inc. reported the year ended December 31, 2023 results: revenue $65.0 million, net income net loss of $4.4 million.

Period: the year ended December 31, 2023
Revenue: $65.0 million
Net income: net loss of $4.4 million
Result: reported results

Exact text from the filing

For the year ended December 31, 2023, Sanara generated net revenues of $65.0 million

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.